Today: 17 June 2026

Keel Stock in Focus Monday After $400M AI Debt Raise

Keel Stock in Focus Monday After $400M AI Debt Raise

Keel Infrastructure shares rose 3.1% to $5.29 in pre-market trading after pricing an upsized $400 million convertible note deal to fund AI data-center expansion, partially recovering from Friday’s 13.5% drop driven by dilution concerns; the company aims to use proceeds for equipment deposits and hedging, with investors watching for future lease signings as the next key milestone.
8 June 2026
··
MPS Shares Surge After Intesa Launches €30.6 Billion Offer

MPS Shares Surge After Intesa Launches €30.6 Billion Offer

Banca Monte dei Paschi di Siena shares soared 10.91% to 9.921 euros after Intesa Sanpaolo launched an unsolicited €30.6 billion cash-and-share bid, offering a 12.5% premium and triggering takeover rules that block MPS from merging with Banco BPM without shareholder approval, as investors weigh regulatory hurdles, branch disposals, and the fight for control of key Italian financial assets.
8 June 2026
··
Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma shares plunged 26.02% to 241.40 Danish crowns after investors focused on a 19% discontinuation rate for Boehringer’s obesity drug survodutide in the SYNCHRONIZE-1 trial, far higher than the 2.9% for placebo, despite strong fat-loss data, making the stock the worst performer on Europe’s STOXX 600 in early trade.
8 June 2026
·
Intel’s AI Stock Run Stalls; Monday Premarket Move Fails to Settle It

Intel’s AI Stock Run Stalls; Monday Premarket Move Fails to Settle It

Intel shares rose 1.6% to $100.74 in pre-market trading Monday, partly rebounding from Friday’s 7.9% drop that followed a strong U.S. jobs report and a tech selloff; investors now face a key test as Intel’s AI partnerships with Foxconn and others lack visible orders or financial details, while options pricing signals potential for another 9% stock move this week amid inflation data and shifting rate expectations.
8 June 2026
Nvidia’s $5 Trillion Valuation Gets Put to the Test Monday

Nvidia’s $5 Trillion Valuation Gets Put to the Test Monday

Nvidia shares hovered near Friday’s 6% drop and $300 billion market cap loss despite new South Korean AI deals, as chip stocks reeled from fears of higher U.S. rates and regulatory risks; investors await Monday’s open to see if fresh partnerships can offset sector volatility and valuation pressure.
8 June 2026
Nokia drops after fast AI rally, traders stay focused

Nokia rally stalls as traders sell tech stocks after AI push

Nokia shares plunged 2.98% in Helsinki to 12.690 euros, extending losses as investors dumped AI-linked tech stocks amid rising oil prices and rate fears; U.S. ADRs dropped 13.48% Friday, while no new operating update was given and Nokia issued 500 million euros in new debt, with the next key earnings test set for July 23.
8 June 2026
SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX’s $75 billion IPO launches June 12 at $135 a share, with retail demand already double the shares on offer and 30% of the deal earmarked for individuals, but 2025 losses of $4.94 billion and a $1.75 trillion target valuation raise questions about post-IPO pricing as index entry and profitability remain uncertain.
8 June 2026
Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly closed at $1,131.42, up 0.55%, after releasing late-stage data showing its obesity drug retatrutide led to 28.3% weight loss over 80 weeks and reduced sleep apnea and knee pain, fueling hopes its obesity pipeline could expand beyond weight loss as rivals Boehringer Ingelheim and Zealand Pharma unveiled competing data, setting up a key test for Lilly’s trillion-dollar valuation as trading resumes.
8 June 2026
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 9, 2026, 3:59 AM EDT Smiths Group (LSE:SMIN) Fair Value Holds Steady Amid Evolving Market Narrative June 9, 2026, 3:59 AM EDT. Smiths Group’s (LSE:SMIN) latest analyst update shows no change to its fair value estimate, maintaining current assumptions on revenue growth, profit margins, P/E ratio, and discount rate. The steady valuation indicates confidence in the company’s long-term outlook despite evolving market narratives. Investors monitor risks like project execution and regulatory changes, while tracking potential impacts from contract wins and strategic shifts. Simply Wall St’s narrative tool aids in connecting
8 June 2026
·
Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
8 June 2026
·
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
8 June 2026
······
1 … 40 41 42 43 44 … 2,076

Stock Market Today

  • IceCure Medical Shares Surge on U.S. ProSense Install Base Growth Post-FDA Approval
    June 17, 2026, 11:59 AM EDT. IceCure Medical shares surged over threefold to $7.17 following a 70% increase in the U.S. commercial install base of its ProSense cryoablation system for breast cancer, since FDA approval in October 2025. The Israeli firm's device, designed for low-risk breast cancer patients aged 70 and older, is gaining traction with growing physician interest and patient awareness. The stock jump followed a 1-for-30 reverse stock split aimed at meeting Nasdaq's $1.00 minimum bid price rule by November 2026. ProSense procedures have expanded in major U.S. cities, and increased sales leads were reported from key breast imaging and surgery symposiums. Competition remains from established players in cryoablation, including Varian/Siemens Healthineers and Boston Scientific.

Latest articles

IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance

IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance

17 June 2026
In this article, you’ll find answers to your questions such as: Why did IceCure Medical shares more than triple in late-morning Nasdaq trading? What is driving the sharp rise in U.S. commercial adoption of the ProSense breast-cancer cryoablation system? How significant is the 70% increase in the U.S. install base since FDA authorization? What risks does the company still face, and what are the next steps for investors to watch?
Plug Power stock rebounds as traders weigh cash moves, margin gains

Plug Power stock rebounds as traders weigh cash moves, margin gains

17 June 2026
In this article, you'll find answers to your questions: Why did Plug Power shares rebound after a recent drop? What recent liquidity steps and margin improvements has the company made? How did the sale of a federal investment tax credit impact Plug’s financial position? What risks does Plug Power face regarding costs, cash use, and project execution? What are the latest revenue and margin figures?
AMC keeps running after $150 million share sale lifts cash, raises dilution questions

AMC keeps running after $150 million share sale lifts cash, raises dilution questions

17 June 2026
In this article, you’ll find answers to your questions: Why did AMC shares jump after the $150 million equity sale? How does the new cash position affect AMC’s heavy debt and lease obligations? What does strong May attendance mean for future revenue? Why is dilution still a major risk for investors? How are Wall Street analysts reacting to these developments?
Go toTop